Latest market price
39.04
-0.66-1.66%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.97 | Insider Own | 3.30% | Shs Outstand | 32.26M | Perf Week | -0.76% |
| Market Cap | 1.26B | Forward P/E | — | EPS next Y | -5.32 | Insider Trans | 26.88% | Shs Float | 23.92M | Perf Month | 5.54% |
| Enterprise Value | 935.40M | PEG | — | EPS next Q | -1.62 | Short Float | 23.26% | Perf Quarter | -13.24% | ||
| Income | -86.00M | P/S | — | EPS this Y | — | Short Ratio | 14.71 | Perf Half Y | 22.65% | ||
| Sales | 0.00 | P/B | 3.79 | EPS next Y | — | ROA | -23.69% | Short Interest | 5.56M | Perf YTD | 75.38% |
| Book/sh | 10.29 | P/C | 3.84 | EPS next 5Y | — | ROE | -25.91% | 52W High | 50.16 -22.17% | Perf Year | 139.80% |
| Cash/sh | 10.17 | P/FCF | — | EPS past 3/5Y | — | ROIC | -28.07% | 52W Low | 14.32 172.63% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.02% 6.41% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 2.29 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 15.08 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 50.13 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 15.08 | EPS Q/Q | -18.75% | SMA20 | 3.65% | Beta | 0.57 | Target Price | 59.78 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -5.25% | Rel Volume | 1.30 | Prev Close | 39.70 |
| Employees | 49 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 19.52% | Avg Volume | 358.74K | Price | 39.04 |
| IPO Date | Sep 11, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -112.78% — | Net Debt/EBITDA | — | Volume | 466,446 | Change | -1.66% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-09-26 | Initiated | Canaccord | Buy | $65 |
| Oct-05-26 | Initiated | Guggenheim | Buy | $80 |
| Oct-05-26 | Downgrade | Roth Capital | Buy → Neutral | $37 → $35 |
| Oct-02-26 | Initiated | Needham | Buy | $68 |
| Aug-24-26 | Reiterated | HC Wainwright & Co. | Buy | $45 → $60 |
| Aug-13-26 | Reiterated | Stifel Nicolaus | $40 → $53 | |
| Aug-12-26 | Reiterated | BMO Capital | Outperform | $46 → $54 |
| Aug-03-26 | Reiterated | Piper Sandler | $78 | |
| Jul-20-26 | Initiated | BMO Capital | Outperform | $46 |
| Jul-07-26 | Initiated | Wolfe Research | Outperform | $45 |
Latest News· Times ET
Oct-28-26
Oct-27-26
Oct-27-2609:04PM
Oct-15-26
Oct-10-26
Oct-06-26
Oct-06-2608:00AM
Oct-02-26
Oct-02-2604:24AM
Sep-28-26
Sep-28-2603:29AM
Sep-18-26
Sep-18-2604:25AM
Sep-15-26
Sep-09-26
Sep-09-2608:00AM
Sep-03-26
Sep-03-2604:05PM
08:00AM
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officerglobenewswire.com
04:07AM
Aug-24-26
Aug-24-2605:30AM
Company
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | |
| Selling, General and Administrative Excl. Other | 25 | 14 | 14 | 4 | — | |
| Research and Development | 69 | 17 | 51 | 8 | — | |
| Other Operating Expense | 1 | -1 | 0 | -1 | — | |
| Operating Income | -95 | -30 | -65 | -11 | — | |
| Interest Expense | 0 | 0 | 0 | 5 | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | 5 | 2 | 10 | — | |
| Net Income Before Taxes | -86 | -25 | -63 | -6 | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | |
| Consolidated Net Income | -86 | -25 | -63 | -6 | — | |
| Net Income From Continuing Operations | -86 | -25 | -63 | -6 | — | |
| Net Income | -86 | -25 | -63 | -6 | — | |
| EPS (Recurring) | -2.97 | -1.00 | -17.83 | -1.77 | — | |
| EPS (Basic, Before Extraordinaries) | -2.97 | -1.00 | -17.83 | -1.77 | — | |
| EPS (Diluted) | -2.97 | -1.00 | -17.83 | -1.77 | — | |
| EBITDA | -87 | -25 | -63 | -1 | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | |
| Shares Outstanding | 30 | 25 | 4 | 4 | — | |
| Market Capitalization | 1,171 | 557 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 10% Owner | Jul 30 '26 | Buy | 0.00 | 286,205 | 29 | 664,649 | Aug 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.